Search

REGENXBIO Inc

Open

BrancheGesundheitswesen

8.9 10.56

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.73

Max

8.66

Schlüsselkennzahlen

By Trading Economics

Einkommen

113M

23M

Verkäufe

102M

108M

EPS

0.43

Gewinnspanne

21.023

Angestellte

371

EBITDA

112M

34M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+175.68% upside

Dividenden

By Acuity

Nächstes Ergebnis

5. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

128M

748M

Vorheriger Eröffnungskurs

-1.66

Vorheriger Schlusskurs

8.9

Nachrichtenstimmung

By Acuity

58%

42%

291 / 340 Ranking in Healthcare

REGENXBIO Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Aug. 2026, 19:51 UTC

News
Social Media
Event

Regenxbio Inc shares are lower following the FDA's clinical hold on RGX-121 due to MRI findings, with Bank of America maintaining a $15 price target.

21. Aug. 2026, 19:26 UTC

Regenxbio Inc shares are declining today amid notable volatility, pulling back significantly from an earlier peak during the session. No specific news was identified.

20. Aug. 2026, 20:02 UTC

Regenxbio Inc. shares are lower as biotechnology stocks face pressure today, with no specific news identified to explain the decline.

19. Aug. 2026, 22:06 UTC

Regenxbio Inc shares are higher in after-market trading, continuing a positive trend since Wednesday's close and remaining above their 20-day moving average.

18. Aug. 2026, 19:46 UTC

Regenxbio Inc's shares are lower today amid rising Treasury yields and inflation concerns. The stock remains above its 20-day moving average.

17. Aug. 2026, 20:06 UTC

Regenxbio Inc shares are higher today, reflecting strong market performance. The stock remains near its one-month high and above its 20-day moving average.

14. Aug. 2026, 19:36 UTC

Regenxbio Inc shares are higher during Friday's session, advancing despite a reported decline in retail sales for July.

13. Aug. 2026, 21:31 UTC

Regenxbio Inc shares are lower in after-market hours, pulling back from an earlier session high. No specific news was identified to explain the decline.

12. Aug. 2026, 19:41 UTC

Regenxbio Inc shares are higher today amid positive market sentiment following a modest increase in the core Consumer Price Index.

11. Aug. 2026, 19:11 UTC

Biotechnology stocks are advancing today, contributing to Regenxbio Inc's higher price movement. The stock pulled back earlier but remains in positive territory overall.

10. Aug. 2026, 19:46 UTC

News

Regenxbio Inc shares are lower today after H.C. Wainwright cut its price target to $23.00, despite a strong Q2 earnings report.

7. Aug. 2026, 20:06 UTC

News

Barclays downgraded Regenxbio Inc to Equal-Weight from Overweight, maintaining a $12 price target. Shares are trading lower amid concerns about growth prospects.

6. Aug. 2026, 23:31 UTC

News

Regenxbio Inc shares are higher in after-market hours following key milestones in its Q2 2026 earnings call, including FDA alignment for RGX-202's development.

5. Aug. 2026, 19:26 UTC

Regenxbio Inc shares are higher during Wednesday's session, despite intraday volatility. Broader market sentiment is influenced by a recent decline in crude oil prices.

4. Aug. 2026, 19:56 UTC

Regenxbio Inc shares are higher, reflecting market strength amid a decline in crude oil prices that eased inflation concerns. No specific company news was identified.

31. Juli 2026, 19:36 UTC

Regenxbio Inc shares are lower, influenced by declines in the Biotechnology sector. The stock showed volatility, briefly rising earlier in the session.

30. Juli 2026, 19:29 UTC

Regenxbio Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday. The stock remains below its 20-day moving average.

29. Juli 2026, 19:56 UTC

Macro Event

Regenxbio Inc is trading higher as the Federal Reserve maintains interest rates, reflecting heightened market sensitivity amid ongoing economic growth and geopolitical tensions.

28. Juli 2026, 18:16 UTC

Regenxbio Inc shares are lower, continuing a three-day decline amid broader market pressures, including losses in Asian markets like the Nikkei 225 Index.

27. Juli 2026, 19:36 UTC

Regenxbio Inc is trading higher during Monday's session, recovering from earlier declines. Broader market sentiment is influenced by a significant drop in oil prices.

24. Juli 2026, 20:07 UTC

Regenxbio Inc shares are lower today, continuing a decline since Thursday's close. The stock remains below its 20-day moving average, indicating market weakness.

22. Juli 2026, 18:26 UTC

Regenxbio Inc shares are lower amid geopolitical tensions and rising crude oil prices. Earlier in the session, shares briefly recovered but have since declined.

21. Juli 2026, 19:31 UTC

Regenxbio Inc is higher during Tuesday's session, tracking the broader market's gains amid positive sentiment from recent earnings reports. No specific company news was identified.

20. Juli 2026, 19:31 UTC

Event
News
Social Media

Regenxbio shares rise after positive long-term trial results for surabgene lomparvovec, showing sustained vision improvements in patients with retinal conditions.

Peer-Vergleich

Kursveränderung

REGENXBIO Inc Prognose

Kursziel

By TipRanks

175.68% Vorteil

12-Monats-Prognose

Durchschnitt 22.22 USD  175.68%

Hoch 42 USD

Tief 10 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für REGENXBIO Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

7

Buy

2

Halten

0

Sell

Stimmung

By Acuity

291 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
help-icon Live chat